Safety of 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma Previously Treated With External Beam Radiation Therapy
Latest Information Update: 29 Jun 2023
At a glance
- Drugs Omburtamab-I-131 (Primary)
- Indications Diffuse intrinsic pontine glioma
- Focus Adverse reactions
- Sponsors Y-mAbs Therapeutics
- 22 Jun 2023 Planned End Date changed from 31 Jan 2027 to 1 Dec 2026.
- 22 Jun 2023 Planned primary completion date changed from 31 Dec 2025 to 1 Mar 2026.
- 22 Jun 2023 Planned initiation date changed from 1 Mar 2023 to 1 Mar 2022.